Related Experiment Video
Updated: Jun 27, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
An siENPP1-Delivering Bimetallic MOF Nanocomplex Enables Triple Activation of the cGAS-STING Pathway for Synergistic
Shi Chen1, Mengjia Shi2, Yi Chen1
1College of Laboratory Medicine, Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), Chongqing Medical University, Chongqing, P. R. China.
Abstract:
Triple-negative breast cancer (TNBC) is associated with poor prognosis due to its highly heterogeneous tumor immune microenvironment and the lack of actionable molecular targets, which collectively limit the efficacy of current therapies. To address these challenges, PEI/siENPP1@Mn-ZIF-8 (PEMZ) is reported, an integrated gene-chemodynamic-immune nanocomplex that activates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway through a previously unattainable triple-activation mechanism. PEMZ efficiently encapsulates siENPP1, protects it from degradation, and enables acid-responsive cytosolic release, resulting in sustained ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) silencing and accumulation of tumor-derived cyclic 2',3'-GMP-AMP (cGAMP). Simultaneously, the Mn2+/Zn2+ ions released from the trienzyme-mimetic nanocomplex, which exhibits peroxidase-, catalase-, and glutathione peroxidase-like activities, amplify intracellular reactive oxygen species, deplete glutathione, and trigger mitochondrial dysfunction. This coordinated redox disruption induces immunogenic cell death and further enhances STING signaling. In vitro and in vivo studies demonstrate that PEMZ markedly suppresses TNBC proliferation and metastasis, promotes dendritic cell maturation, and increases intratumoral CD8+ T-cell infiltration, achieving potent tumor inhibition with minimal systemic toxicity. This work establishes PEMZ as a mechanistically integrated nano-immunotherapy platform, offering a promising and broadly applicable strategy for the precision treatment of TNBC and other ENPP1-overexpressing cancers.
Insights
A novel nanocomplex, PEI/siENPP1@Mn-ZIF-8 (PEMZ), effectively targets triple-negative breast cancer (TNBC) by activating the cGAS-STING pathway. This integrated nano-immunotherapy shows potent tumor inhibition with minimal toxicity.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Research
Background:
- Triple-negative breast cancer (TNBC) presents a poor prognosis due to its complex tumor immune microenvironment and limited therapeutic targets.
- Current treatments for TNBC are often limited in efficacy, necessitating novel therapeutic strategies.
Purpose of the Study:
- To develop an integrated gene-chemodynamic-immune nanocomplex for enhanced TNBC treatment.
- To investigate the mechanism of action of PEI/siENPP1@Mn-ZIF-8 (PEMZ) in activating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway.
Main Methods:
- Encapsulation of siENPP1 within a Mn-ZIF-8 framework (PEMZ) for acid-responsive release and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) silencing.
- Utilizing the trienzyme-mimetic properties of released Mn2+/Zn2+ ions to induce redox disruption and reactive oxygen species (ROS) amplification.
- Evaluating PEMZ's efficacy in vitro and in vivo for TNBC suppression, immune cell modulation, and overall tumor inhibition.
Main Results:
- PEMZ achieved sustained ENPP1 silencing and accumulation of cyclic 2',3'-GMP-AMP (cGAMP), activating the cGAS-STING pathway.
- The nanocomplex induced immunogenic cell death and enhanced STING signaling through coordinated redox disruption.
- PEMZ significantly suppressed TNBC proliferation and metastasis, promoted dendritic cell maturation, and increased intratumoral CD8+ T-cell infiltration.
Conclusions:
- PEMZ acts as a mechanistically integrated nano-immunotherapy platform for TNBC treatment.
- The triple-activation mechanism of PEMZ offers a promising strategy for precision treatment of TNBC and other ENPP1-overexpressing cancers.
- This approach demonstrates potent tumor inhibition with minimal systemic toxicity.
